🇺🇸 Vir Biotechnology, Inc.VIR

Company Update Form 8-K 09-11-2026 08:31:22 EST

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Announces Phase 3 ECLIPSE 1 trial results meeting primary endpoint with a 44% response rate for elebsiran and tobevibart in chronic hepatitis delta.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest